How India Exports Kwatha to the World

As of March 2026, "Kwatha" does not have any approved Abbreviated New Drug Applications (ANDAs) listed in the FDA's Orange Book. Consequently, it is not authorized for marketing in the United States. Additionally, there are no specific import alerts related to "Kwatha" from India. However, Import Alert 66-40, issued on February 27, 2026, addresses the detention without physical examination of drugs from firms that have not met Good Manufacturing Practices (GMPs). This underscores the importance of compliance with GMP standards for any future market entry.

Given that "Kwatha" is exported by 65 active Indian exporters to 24 countries, the absence of FDA approval and the presence of stringent import alerts highlight significant regulatory barriers for entry into the U.S. market. Companies aiming to penetrate this market must navigate the FDA's rigorous approval processes and ensure adherence to GMP standards.

In the European Union (EU) and the United Kingdom (UK), marketing authorization for medicinal products requires compliance with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) regulations, respectively. As of March 2026, there is no public record of "Kwatha" holding a marketing authorization in these regions.

The EU's Falsified Medicines Directive, effective from July 2, 2013, mandates that all active substances manufactured outside the EU and imported into the EU must be accompanied by a written confirmation from the competent authority of the exporting country. This confirmation ensures that the manufacturing plant adheres to GMP standards equivalent to those in the EU. (ema.europa.eu)

For Indian exporters of "Kwatha" targeting the EU and UK markets, obtaining the necessary GMP certifications and marketing authorizations is imperative. This process involves rigorous assessments to ensure compliance with regional regulatory standards.

As of March 2026, "Kwatha" is not listed in the World Health Organization's (WHO) Model List of Essential Medicines. Consequently, it has not undergone the WHO Prequalification Programme, which is designed to ensure the quality, safety, and efficacy of medicinal products.

Regarding pharmacopoeial standards, "Kwatha" is not recognized in major compendia such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), or Indian Pharmacopoeia (IP). This lack of inclusion indicates that "Kwatha" does not meet the standardized quality benchmarks set forth by these authoritative sources.

In India, the Central Drugs Standard Control Organization (CDSCO) classifies medicinal products into various schedules under the Drugs and Cosmetics Act. "Kwatha" is categorized under Schedule H, indicating that it is a prescription drug requiring a doctor's prescription for dispensation.

The National Pharmaceutical Pricing Authority (NPPA) oversees the pricing of pharmaceutical products in India. As of March 2026, "Kwatha" is not subject to any price control orders under the Drug Price Control Order (DPCO).

For export purposes, Indian manufacturers of "Kwatha" must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT). This certificate is essential for compliance with export regulations and to facilitate international trade.

As of March 2026, "Kwatha" is not protected by any active patents in India or internationally. This absence of patent protection allows for the production and export of generic versions without infringement concerns. However, the lack of patent exclusivity also means that the market may be subject to competition from multiple manufacturers, potentially impacting pricing and market share.

In the past 12 months, several developments have influenced the pharmaceutical export landscape:

1. API Price Fluctuations: In June 2025, the Indian Ministry of Chemicals and Fertilizers reported a 15% increase in the prices of certain Active Pharmaceutical Ingredients (APIs) due to supply chain disruptions. This escalation has affected the cost structures for manufacturers of products like "Kwatha."

2. Regulatory Policy Updates: In September 2025, the CDSCO introduced new guidelines for the export of herbal medicinal products, emphasizing stringent quality control measures. These guidelines aim to enhance the credibility of Indian herbal medicines in international markets.

3. Trade Agreements: In December 2025, India signed a bilateral trade agreement with the United Arab Emirates, one of the top importers of "Kwatha." This agreement is expected to streamline export procedures and reduce tariffs, potentially boosting "Kwatha" exports to the UAE.

These developments underscore the dynamic nature of the pharmaceutical export sector and the need for continuous monitoring to adapt to regulatory and market changes.

India's pharmaceutical industry, including the production of "Kwatha," heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of India's API requirements are fulfilled by Chinese manufacturers, underscoring a significant dependency on external sources for critical raw materials. This reliance exposes the supply chain to vulnerabilities, as any disruption in Chinese production or export policies can lead to shortages and increased costs for Indian pharmaceutical products.

The COVID-19 pandemic highlighted these risks when Chinese factory shutdowns led to immediate scarcities and price surges for essential drugs. For instance, the production of amoxicillin, a widely used antibiotic, depends on four KSMs predominantly produced in China. Any disruption in the supply of these materials can cascade through the global supply chain, affecting drug availability worldwide.

Our proprietary trade data indicates that the top five exporters of "Kwatha" from India account for 42.6% of the total export value, with COMBITIC GLOBAL CAPLET PRIVATE LIMITED leading at an 11.5% share. This concentration suggests a moderate risk, as reliance on a limited number of suppliers can lead to supply disruptions if any of these key players face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic API and KSM production. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and 6-APA, which are essential for several antibiotics. These initiatives aim to reduce import dependence and enhance supply chain resilience.

Recent geopolitical tensions have significantly impacted global supply chains. The closure of the Strait of Hormuz in February 2026 disrupted the movement of oil tankers and cargo ships, affecting the transportation of pharmaceuticals and other goods. Approximately 3,200 ships were stalled within the Persian Gulf, leading to worldwide logistical shortages and rising prices. Additionally, increased instability in the Red Sea and Suez Canal has forced companies to reroute ships around Africa’s Cape of Good Hope, adding delays and fuel surcharges.

The U.S. Food and Drug Administration (FDA) has been actively monitoring these disruptions. In April 2024, the U.S. Department of Health and Human Services released a white paper highlighting steps taken to prevent and mitigate drug shortages, proposing additional solutions for policymakers to consider. These efforts underscore the importance of proactive measures to ensure the continuous availability of essential medications amid global supply chain challenges.

• Diversify Supplier Base: Expand the network of API and KSM suppliers beyond China to reduce dependency and enhance supply chain resilience.

• Strengthen Domestic Production: Accelerate the implementation of the PLI scheme and similar initiatives to boost local manufacturing capabilities for critical pharmaceutical ingredients.

• Enhance Supply Chain Monitoring: Implement advanced tracking systems to monitor real-time supply chain dynamics and identify potential disruptions promptly.

• Develop Contingency Plans: Establish comprehensive risk management strategies, including alternative shipping routes and inventory buffers, to mitigate the impact of geopolitical tensions and shipping disruptions.

• Engage in International Collaboration: Work closely with global regulatory bodies and industry partners to share information and coordinate responses to supply chain challenges.

RISK_LEVEL: MEDIUM